Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00212056
Status:
COMPLETED
Last Update Posted:
2007-11-01
First Post:
2005-09-13
Brief Title:
Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by ANP
Sponsor:
National Cerebral and Cardiovascular Center Japan
Organization:
National Cerebral and Cardiovascular Center Japan
Study Overview
Official Title:
Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by ANP
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate whether ANP as an adjunctive therapy for AMI reduces myocardial infarct size and improves regional wall motion
Detailed Description:
The benefits of percutaneous coronary intervention PCI in acute myocardial infarction AMI are limited by reperfusion injury In animal models atrial natriuretic peptide ANP reduces infarct size so the Japan-Working groups of acute myocardial Infarction for the reduction of Necrotic Damage by ANPJ-WINDANP designed a prospective randomized multicenter study to evaluate whether ANP as an adjunctive therapy for AMI reduces myocardial infarct size and improves regional wall motion
Twenty hospitals in Japan will participate in the J-WIND-ANP study Patients with AMI who are candidates for PCI are randomly allocated to receive either intravenous ANP or placebo administration The primary end-points are 1 estimated infarct size Σcreatine kinase and troponin T and 2 left ventricular function left ventriculograms Single nucleotide polymorphisms SNPs that may be associated with the function of ANP and susceptibility of AMI will be examined Furthermore a data mining method will be used to design the optimal combinational therapy for post-MI patients
J-WIND-ANP will provide important data on the effects of ANP as an adjunct to PCI for AMI and the SNPs information will open the field of tailor-made therapy The optimal therapeutic drug combination will also be determined for post-MI patients
Twenty hospitals in Japan will participate in the J-WIND-ANP study Patients with AMI who are candidates for PCI are randomly allocated to receive either intravenous ANP or placebo administration The primary end-points are 1 estimated infarct size Σcreatine kinase and troponin T and 2 left ventricular function left ventriculograms Single nucleotide polymorphisms SNPs that may be associated with the function of ANP and susceptibility of AMI will be examined Furthermore a data mining method will be used to design the optimal combinational therapy for post-MI patients
J-WIND-ANP will provide important data on the effects of ANP as an adjunct to PCI for AMI and the SNPs information will open the field of tailor-made therapy The optimal therapeutic drug combination will also be determined for post-MI patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UMIN_IDC000000088 | None | None | None |